Abstract
Originally, nuclear medicine focused on radiopharmaceuticals trapped in organ structures, based on their function, and the presence of disease was seen by the absence of radioactivity. More recently, target-specific radiopharmaceuticals have been developed to visualize and/or treat oncological diseases. Since radiopharmaceuticals have historically a leading position in the search for “molecular imaging”, it would be a waste not to learn from the pitfalls and opportunities that have been and are found during the development of radiopharmaceuticals. This knowledge can be used in the improvement of contrast agents for other imaging modalities like MRI and CT. In this article the aspects that are needed for the use of current and future therapeutic and diagnostic radiopharmaceuticals are described. Especially the production and development of therapeutic and imageable radiopharmaceuticals are demonstrated. MRI or CT can sometimes also image stable isotopes of elements that contain useful radionuclides. This can result in real multimodality imaging. Combining imaging modalities and imaging agents will result in better patient care and can only be advantageous if all departments and institutes will collaborate on their research work. The combination of approaches together with the fast progress in developments in the medical imaging world will result in a bright future for imaging driven therapy of cancer.
Keywords: holmium, MRI, SPECT, PET/CT, cancer, multimodality, molecular imaging, Radionuclides
Anti-Cancer Agents in Medicinal Chemistry
Title: The Bright Future of Radionuclides for Cancer Therapy
Volume: 7 Issue: 3
Author(s): Johannes Franciscus Wilhelmus Nijsen, Gerard Cornelis Krijger and Afred Dirk van het Schip
Affiliation:
Keywords: holmium, MRI, SPECT, PET/CT, cancer, multimodality, molecular imaging, Radionuclides
Abstract: Originally, nuclear medicine focused on radiopharmaceuticals trapped in organ structures, based on their function, and the presence of disease was seen by the absence of radioactivity. More recently, target-specific radiopharmaceuticals have been developed to visualize and/or treat oncological diseases. Since radiopharmaceuticals have historically a leading position in the search for “molecular imaging”, it would be a waste not to learn from the pitfalls and opportunities that have been and are found during the development of radiopharmaceuticals. This knowledge can be used in the improvement of contrast agents for other imaging modalities like MRI and CT. In this article the aspects that are needed for the use of current and future therapeutic and diagnostic radiopharmaceuticals are described. Especially the production and development of therapeutic and imageable radiopharmaceuticals are demonstrated. MRI or CT can sometimes also image stable isotopes of elements that contain useful radionuclides. This can result in real multimodality imaging. Combining imaging modalities and imaging agents will result in better patient care and can only be advantageous if all departments and institutes will collaborate on their research work. The combination of approaches together with the fast progress in developments in the medical imaging world will result in a bright future for imaging driven therapy of cancer.
Export Options
About this article
Cite this article as:
Franciscus Wilhelmus Nijsen Johannes, Cornelis Krijger Gerard and Dirk van het Schip Afred, The Bright Future of Radionuclides for Cancer Therapy, Anti-Cancer Agents in Medicinal Chemistry 2007; 7 (3) . https://dx.doi.org/10.2174/187152007780618207
DOI https://dx.doi.org/10.2174/187152007780618207 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
Call for Papers in Thematic Issues
Induction of cell death in cancer cells by modulating telomerase activity using small molecule drugs
Telomeres are distinctive but short stretches present at the corners of chromosomes and aid in stabilizing chromosomal makeup. Resynthesis of telomeres supported by the activity of reverse transcriptase ribonucleoprotein complex telomerase. There is no any telomerase activity in human somatic cells, but the stem cells and germ cells undergone telomerase ...read more
Role of natural compounds as anti anti-cancer agents
Cancer is considered the leading cause of worldwide mortality, accounting for nearly 10 million deaths in 2022. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy remains an important approach in treatment o f several types of cancers, even though ...read more
Signaling and enzymatic modulators in cancer treatment
Cancer accounts for nearly 10 million deaths in 2022 and is considered the leading cause of worldwide mortality. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy, radiotherapy and surgery are the most important approach for the treatment of several ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Current Understanding of the Role of Dendritic Cells and Their Co-Stimulatory Molecules in Generating Efficient T Cell Responses in Lepromatous Leprosy
Current Immunology Reviews (Discontinued) Methods of Screening-Purification and Antimicrobial Potentialities of Bacteriocin in Health Care
Current Drug Metabolism Patent Selections
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Design, Synthesis and Anticancer Activity of New Thiazole-Tetrazole or Triazole Hybrid Glycosides Targeting CDK-2 via Structure-Based Virtual Screening
Mini-Reviews in Medicinal Chemistry PD1/PD-L1 Axis in Uro-oncology
Current Drug Targets Recent Patents in Pulmonary Delivery of Macromolecules
Recent Patents on Drug Delivery & Formulation Meet Our Editorial Board Member:
Anti-Cancer Agents in Medicinal Chemistry Comparative Proteomics of Liver of the Diabetic Obese db/db and Non-Obese or Diabetic Mice
Current Proteomics Trans-Platinum Complexes in Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Design of N-substituted Amino Caproic Hydroxamic Acid Histone Deacetylase Inhibitors Reveal an Essential Role for Cap Atomic Composition
Anti-Cancer Agents in Medicinal Chemistry Design of Zein Conjugation and Surface Modification for Targeting Drug Delivery
Current Drug Targets Heat Shock Protein 90 Inhibitors in Oncology
Current Proteomics Copper Complexes of 8-Aminoquinoline and Uracils as Novel Aromatase Inhibitors
Letters in Drug Design & Discovery Beneficial Effects of Bioactive Phospholipids: Genomic Bases
Current Nutrition & Food Science Formulation, Characterization and <i>In-vitro</i> and <i>In-vivo</i> Evaluation of Capecitabine Loaded Niosomes
Current Drug Delivery Non-Analgesic Effects of Opioids: Management of Opioid-Induced Constipation by Peripheral Opioid Receptor Antagonists: Prevention or Withdrawal?
Current Pharmaceutical Design Roles of Laminin-332 and α6β4 Integrin in Tumor Progression
Mini-Reviews in Medicinal Chemistry The Role of Hesperidin in Cell Signal Transduction Pathway for the Prevention or Treatment of Cancer
Current Medicinal Chemistry Aromatase: The Enzyme and Its Inhibition
Anti-Cancer Agents in Medicinal Chemistry Griseofulvin Derivatives: Synthesis, Molecular Docking and Biological Evaluation
Current Topics in Medicinal Chemistry